Results 121 to 130 of about 1,604,147 (168)

Erenumab for Chronic Cluster Headache: A Randomized Clinical Trial.

JAMA Netw Open
Mecklenburg J, Gaul C, Fitzek M, Overeem LH, Heinze A, Fleischmann R, Boeger A, Holle-Lee D, Straube A, Gendolla A, Israel-Willner H, Lorenz M, Gossrau G, Naegel S, Rimmele F, Rattan S, Materne B, Schulze D, Raffaelli B, Reuter U, CHERUB01 Study Group.   +20 more
europepmc   +1 more source

Characterization of WAC interactions with R2TP and TTT chaperone complexes linking glucose and glutamine availability to mTORC1 activity

FEBS Open Bio, EarlyView.
TTT and R2TP chaperone complexes are required for the assembly and activation of mTORC1. WAC directly interacts with components of TTT, R2TP, and mTORC1, and these interactions are affected by the availability of glucose and glutamine, correlating with changes in mTORC1 activity.
Sofía Cabezudo, Natalia Cuervo, Carmen García‐Martín, Andrés López‐Perrote, Clara Reglero, Adrián Maqueda‐Real, Ana González‐Corpas, Marina Serna, Diego Megías, Alejo Efeyan, Solip Park, Oscar Llorca   +11 more
wiley   +1 more source

Adaptive vs Monthly Support for Weight-Loss Maintenance: A Randomized Clinical Trial.

JAMA Netw Open
Ross KM, Shankar MN, Qiu P, Tian Z, Ruiz J, Anthony L, Perri MG.   +6 more
europepmc   +1 more source

Two‐way inhibition of PAX5 transcriptional activity by PAX5::CBFA2T3

FEBS Open Bio, EarlyView.
PAX5::CBFA2T3 (PAX5‐C) is a fusion protein of the B‐cell transcription factor, PAX5, and is found in B‐cell ALL. We propose a putative model of two‐way inhibition of PAX5 transcriptional activity by PAX5‐C. There are two ways of repression by PAX5‐C: DNA‐binding‐dependent way and HDAC‐dependent way, with either being sufficient for the repression. HDAC
Reina Ueno, Aki Terasaki, Yuiko Imai, Yuri Kimura, Yuna Kojima, Misa Irie, Koya Odaira, Mina Noura, Shuichi Okamoto, Takahiko Yasuda, Shinobu Tsuzuki, Hitoshi Kiyoi, Fumihiko Hayakawa   +12 more
wiley   +1 more source

Reasons for Not Enrolling in a Randomized Clinical Trial and Patient Preferences for Knee Osteoarthritis Treatment. [PDF]

J Patient Exp
Carland A, Weiss-Laxer N, Martindale M, DiVasta A, Freitas M, Haider MN, Bisson L.   +6 more
europepmc   +1 more source

Ro 31‐8220 suppresses bladder cancer progression via enhancing autophagy in vitro and in vivo

FEBS Open Bio, EarlyView.
The pan‐protein kinase C inhibitor Ro‐31‐8220 demonstrates potent anti‐bladder cancer effects both in vitro and in vivo by suppressing migration/invasion, inducing apoptosis and crucially activating autophagy, where blocking autophagy with chloroquine reduces its cell‐killing efficacy, suggesting its promise as a novel therapeutic candidate requiring ...
Shengjun Fu, Yan Tao, Shan Wu, Yuwen Gong, Youli Zhao, Shaomin Niu, Hui Cheng, You Mu, Na Xu, Ying Wang, Jianzhong Lu, Shanhui Liu, Lanlan Li   +12 more
wiley   +1 more source

How Clinical Pharmacology Can Support Clinical Trial Diversity and Inclusion. [PDF]

Clin Transl Sci
Liao MZ, Sawant A, Corrigan B, Haertter S, Otsubo Y, Younis IR, Kasichayanula S, Mehta R.   +7 more
europepmc   +1 more source

Polydatin ameliorates ovalbumin‐induced asthma in a rat model through NCOA4‐mediated ferroautophagy and ferroptosis pathway

FEBS Open Bio, EarlyView.
In this research, a rat model of asthma was created using OVA, and polydatin served as an intervention. By inhibiting ferroautophagy mediated by NCOA4 and averting ferroptosis, polydatin has been demonstrated to reduce asthma. This work presents new ideas for investigating the mechanism of polydatin's ability to alleviate asthma, in addition to ...
Wei Li, Yuwei Tang, Wenkang Liu, Fang Fang, Jiepeng Wang, Chaoyi Fang   +5 more
wiley   +1 more source

The evolving landscape of restrictive cardiomyopathy treatment: clinical trial trends and future directions. [PDF]

Front Cardiovasc Med
Deng B, Liu W.
europepmc   +1 more source